EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE

124 reported adverse events

Drug classes: Dipeptidyl Peptidase 4 Inhibitor [EPC] Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 20
1 OFF LABEL USE 11
2 FATIGUE 10
3 DIARRHOEA 7
4 HEADACHE 6
5 NAUSEA 6
6 VOMITING 6
7 WEIGHT DECREASED 6
8 DIZZINESS 5
9 DRUG INEFFECTIVE 5
See all common reactions for EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE

EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BLOOD TRIGLYCERIDES DECREASED 1 0.0030
1 PANCREATITIS RELAPSING 1 0.0012
2 VACCINATION COMPLICATION 1 0.0012
3 INFECTED BITE 1 0.0012
4 DISCOLOURED VOMIT 1 0.0010
5 CORONAVIRUS TEST POSITIVE 1 0.0010
6 PRODUCT SELECTION ERROR 1 0.0009
7 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 1 0.0008
8 GENITAL RASH 1 0.0007
9 CATHETERISATION CARDIAC 3 0.0007
See all enriched reactions for EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE